Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Aileron initiates phase Ib study of ALRN-6924 in advanced NSCLC

July 2, 2021

Topline phase II data for VAL-083 in patients with recurrent GBM

July 2, 2021

New GTPase KRAS G12C mutant inhibitors discovered at Beta Pharma

July 2, 2021

Omeros discovers mannan-binding lectin serine protease 2 inhibitors

July 2, 2021

Incyte presents new fibroblast growth factor receptor inhibitors

July 2, 2021

Pharmaxis reports inhibition of target enzymes in phase Ic study of PXS-5505 in myelofibrosis

July 1, 2021

First patient dosed in phase I/IIa trial of PRL-02 in metastatic prostate cancer

June 30, 2021

Encouraging phase II results seen with bomedemstat in essential thrombocythemia, myelofibrosis

June 30, 2021

Antitumor activity of novel prodrug TRN-000546

June 30, 2021

Henan Zhiwei Biomedicine, Henan Normal University patent Bruton tyrosine kinase inhibitors

June 30, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...